Pharmacy Podcast Network

Desperation to Discovery Empowered by PGx | PGX For Pharmacists

Few people with a cause walk the talk as boldly and graciously as Christine Von Raesfeld, founder and CEO of People with Empathy. Christine is a pillar of patient advocacy and allyship in the rare and chronic disease community. Through the lens of her lived experiences in healthcare, she has become a champion for patient voices, diversity and inclusion in clinical research, and equitable patient-sponsor partnerships. Christine has brought her unique perspective and honed expertise to countless roles as a featured speaker for numerous conferences on topics ranging from clinical trial recruitment to data & digital rights, from a true patient perspective. She serves as an e-patient scholar with Stanford MedicineX and a Technical Expert Panelist with CMS among other roles. Wherever possible, Christine generates momentum toward progress along her patient advocacy interests and has become a thought leader worldwide, stimulating dialog on a range of topics relevant to patients, clinicians, and industry. As a patient advisor, Christine has assisted several initiatives including the Stanford "Humanwide" Precision Medicine Program and the NIH All of Us Research Program and serves as a board member/advisor to multiple organizations and startups. For her many contributions to the field, she has been named one of the top 100 Women of Influence by Silicon Valley Business Journal, a member of the 2021 HIMSS Future50, and one of Medika Life's 50 most influential voices in healthcare among other distinctions. www.peoplewithempathy.org/

Independent Pharmacy: Strength in Unity | PUTTcast

From pharmacy software to pharmacies themselves - the thing that sets independently owned small business healthcare apart from multi billion dollar corporations is an inextinguishable passion for their patients. 
 
Listen in as co-hosts Monique Whitney and Lauren Young take a deep dive into what it takes to make independent pharmacy successful with special guests Kevin Minassian & Sarah Callioras of Datascan Pharmacy Software. From ensuring patient satisfaction and pharmacy staff happiness, to alternative revenue streams and openly joining forces; when it comes to PBM abuse of the system, shared goals and a unified front are the only way we will win this fight!
 
Click Here to learn more about Datascan Pharmacy Software
 
To learn more about Pharmacists United for Truth & Transparency, visit our website TruthRx.org

Asembia 2023 Spotlight | Part 2

The Pharmacy Podcast Network was a Proud media Partner of the Asembia 2023 Specialty Pharmacy Summit in Las Vegas April 30 through May 4.
 
Listen to Interviews with innovators of Specialty Pharmacy care on this special episode, host Todd Eury 
Fran Gregory - VP Emerging Therapies
Andrew Burns - Chief Growth Officer

Navigating the Board of Pharmacy | Gavel & Pestle

In this episode of Gavel and Pestle, Todd sits down with Lucas W. Morgan, Esq. to discuss the ins and outs of navigating the board of pharmacy. As a lawyer with extensive experience in the field, Lucas shares his insights and tips for pharmacists and pharmacy professionals who may need to interact with the board of pharmacy. From licensing issues to disciplinary actions, Todd and Lucas cover a wide range of topics to help listeners stay informed and prepared. Tune in to learn from their valuable discussion on "Navigating Board of Pharmacy".

Michelle Lewis, PH.D. and David Stack ’76 | Occupation Station

The biopharmaceutical industry is experiencing rapid growth, and the need for a well-trained workforce comes with that. In this episode of Occupation Station, Diane Donato talks with Dr. Michelle Lewis, executive director for the Stack Family Center for Biopharmaceutical Education and Training (CBET) and David Stack, member of the ACPHS Board of Trustees, and CEO of Pacira Pharmaceuticals about how CBET is meeting the hiring needs of the biopharmaceutical industry. CBET was created as an outgrowth of Albany College of Pharmacy and Health Sciences (ACPHS) after the demand for biopharmaceutical training became apparent. Since CBET opened, industry leaders have been reaching out to CBET to help them grow their workforce, and ACPHS graduates have been enrolling in training to advance their careers in biopharmaceuticals. CBET has the added advantage of being able to offer manufacturing services, becoming a crucial partner for many start-up companies. Stack and Dr. Lewis talk about how the industry collaborates with CBET, how ACPHS graduates learn valuable new skills, and how healthcare will grow with advanced biopharmaceutical capabilities.

Insights into the Rare-Ultra Orphan market & the challenges for manufacturers, providers, payers, pharmacies, and patients | NASP

Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare disease / orphan drug market access, assessing current payer perspectives, and offering insights and potential implications of the management of rare disease and orphan drugs. By highlighting the key issues and opportunities, we hope that payers, providers, patients, and biopharmaceutical manufacturers will bridge the access gaps and ensure patients can receive medically necessary therapies to ultimately improve patient outcomes.

Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma | i3Health

i3Health has developed a dual part education activity for pharmacists on Multiple myeloma with special guest Joseph A. Kalis, PharmD, BCOP and Ambulatory Oncology Pharmacy Specialist. Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification. Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Module 1 of this continuing pharmacy education (CPE)–approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.

APhA 2023 Immunization Award Winner Talks About Her Secrets To Success | Pharmacy Crossroads

Look up the word, grit, in the dictionary and you'll see a picture of Chichi Momah, PharmD., and owner of Springfield Pharmacy in Pennsylvania. Momah opened her brand new start from scratch pharmacy in 2012. She weathered some hard times but kept-on-keepin'-on. She shares how taking leadership, finances and other courses helped her bring her pharmacy along and then how she put it in high-gear with immunizations. Momah is the real deal and you'll be inspired and motivated by her remarkable story.

TWIRx | Pharmacist’s Representation in Public Relations, Education, and Cannabis Medicine

The public’s perception of pharmacist’s is generally limited to a retail chain environment even though community retail plays one part of many roles of pharmacists. Community Pharmacy, Hospital Pharmacy, Compounding Pharmacy, Consulting Pharmacy, Ambulatory Care pharmacy, and Regulatory Pharmacy as a few other sectors of healthcare where pharmacists work to keep the public safe. We talk with Dr. Sue Ojageer PharmD, CPGx, PACS – as an author, pharmacogenomics pharmacist, and healthcare influencer about her transforming role from community pharmacist to consultant entrepreneur. Next we welcome back Josh Kent and Steve McCarthy from Cannabis Pharmacy to talk about getting your community pharmacy started with CBD and Cannabis focused business focusing on pain, anxiety, and sleep supplements.

What The Expanded CMS Guidelines Mean for your Medicare Patients | Real-Time Real Talk by Dexcom

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
 
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
About New Expanded Medicare Guidelines
About Hello Dexcom
 
Dexcom Provider website
 
About Medicaid coverage
 
Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.
Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.
 
A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.
Brief Safety Statement
BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom Clarity Safety Information
The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
 
Dexcom G7 User Guide
Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin:A Randomized Clinical Trial.  2021;325(22):2262–2272. doi:10.1001/jama.2021.7444
Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304. Epub 2021 Sep 29. PMID: 34588210; PMCID: PMC8669539.
Psavko S, Katz N, Mirchi T, Green CR. Usability and teachability of continuous glucose monitoring devices in older adults and diabetes educators: a task analysis and ease of use survey. JMIR Hum Factors. 2022 Nov 8. doi: 10.2196/42057
International Hypoglycemia Study Group. Diabetes Care. 2015;38:1583-1591.
Boureau AS, et al. Nocturnal hypoglycemia is underdiagnosed in older people with insulin-treated type 2 diabetes: The HYPOAGE observational study. J Am Geriatr Soc. 2023;1–13. DOI: 10.1111/jgs.18341.
Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 May;16(3):677-682. doi: 10.1177/1932296820982584. Epub 2021 Jan 5. PMID: 33401946; PMCID: PMC9294577.
Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technol Ther. 2019 Apr;21(4):155-158. doi: 10.1089/dia.2018.0359. Epub 2019 Mar 22. PMID: 30896290; PMCID: PMC6477579.
Shichun Bao, Ryan Bailey, Peter Calhoun, and Roy W. Beck.Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin.Diabetes Technology & Therapeutics.May 2022.299-306.http://doi.org/10.1089/dia.2021.0494
By 2023, there had been 52 million ULS alerts from Dexcom CGM systems, and 11 million of those occurred during the night. Dexcom data on file, 2023.